^
Association details:
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
New
Source:
Title:

1477 First efficacy and multi-omic analysis data from phase 1 clinical trial of oncolytic viral immunotherapy with CAN-2409 + valacyclovir in combination with nivolumab and standard of care in newly diagnosed high-grade glioma

Published date:
11/08/2022
Excerpt:
mOS for patients with unmethylated MGMT was 13.2mo (GTR) and 15.9mo (STR)….Combination treatment of CAN-2409/valacyclovir plus nivolumab and SoC induces profound immunological changes and appears to associate with encouraging survival data.
Secondary therapy:
valacyclovir
DOI:
http://dx.doi.org/10.1136/jitc-2022-SITC2022.1477
Trial ID: